HC Wainwright Predicts Ocugen's Q1 Earnings (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Stock analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for Ocugen in a report released on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.05) per share for the quarter, down from their prior forecast of ($0.04). HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Ocugen's current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen's Q2 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, FY2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.11) EPS and FY2028 earnings at $0.21 EPS.

Separately, Chardan Capital increased their price target on Ocugen from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th.

Ocugen Trading Down 5.0 %

Shares of OCGN traded down $0.03 on Monday, hitting $0.55. 1,753,790 shares of the stock traded hands, compared to its average volume of 4,129,515. The firm has a market capitalization of $160.02 million, a P/E ratio of -3.06 and a beta of 3.88. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04. Ocugen has a 1 year low of $0.52 and a 1 year high of $2.11. The stock's 50 day moving average is $0.71 and its two-hundred day moving average is $0.89.

Ocugen (NASDAQ:OCGN - Get Free Report) last released its earnings results on Wednesday, March 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. During the same period in the prior year, the firm earned ($0.03) EPS.

Remove Ads

Institutional Investors Weigh In On Ocugen

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new position in Ocugen during the fourth quarter worth approximately $30,000. Ameriprise Financial Inc. purchased a new position in shares of Ocugen in the 4th quarter worth $30,000. Virtu Financial LLC acquired a new position in Ocugen in the fourth quarter valued at $32,000. Tower Research Capital LLC TRC boosted its holdings in Ocugen by 309.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company's stock valued at $32,000 after acquiring an additional 30,120 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in Ocugen during the fourth quarter valued at about $40,000. 10.27% of the stock is owned by institutional investors and hedge funds.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.